Natera Inc. has announced the completion of enrollment in the ACES-EMB clinical trial, the first randomized-controlled study comparing non-invasive donor-derived cell-free DNA (dd-cfDNA) surveillance using the Prospera Heart test to routine endomyocardial biopsy $(EMB)$ for monitoring heart transplant rejection. The trial enrolled over 300 patients at 17 U.S. transplant centers, with participants randomized one month after transplant to either Prospera-based surveillance or standard EMB-based care. Patients will be followed for 12 months. The results of the study have not yet been presented and are expected in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260128906852) on January 28, 2026, and is solely responsible for the information contained therein.